Format

Send to

Choose Destination
Int J Clin Exp Med. 2015 Jul 15;8(7):11268-75. eCollection 2015.

Therapeutic efficacy of Cernilton in benign prostatic hyperplasia patients with histological prostatitis after transurethral resection of the prostate.

Author information

1
Department of Urology, Affiliated Xinhua Hospital of Shanghai Jiaotong University School of Medicine Shanghai, China.
2
Department of Urology, Shanghai Kongjiang Hospital Shanghai, China.
3
Department of Ultrasound in Medicine, Affiliated Xinhua Hospital of Shanghai Jiaotong University School of Medicine Shanghai, China.
4
Department of Pathology, Affiliated Xinhua Hospital of Shanghai Jiaotong University School of Medicine Shanghai, China.
5
Department of Urology, Affiliated Tenth People's Hospital of Shanghai Tongji University School of Medicine Shanghai, China.
6
Department of Urology, Affiliated Ninth People's Hospital of Shanghai Jiaotong University School of Medicine Shanghai, China.

Abstract

OBJECTIVE:

This study was to prospectively evaluate the therapeutic efficacy of Cernilton in benign prostatic hyperplasia (BPH) patients with histological prostatitis after transurethral resection of the prostate (TURP).

MATERIALS AND METHODS:

One hundred patients with histological prostatitis were recruited from January 2007 to January 2013. All patients were divided into groups A (mild), B (moderate), and C (severe) based on symptom severity, and then randomly subgrouped into Cernilton group and control group. Patients in Cernilton group were treated with Cernilton for 3 months after TURP, while patients in control group received placebo. A series of patient indicators were evaluated before, perioperatively (peri), and after TURP.

RESULTS:

The assessed indicators remained unchanged peri-TURP as compared to those before surgery. 6 months after TURP, indicators remained stable in group A, and significant differences were observed in the International Index of Erectile Function-5 (IIEF-5) in group B and in the storage symptom score (Ss), quality of life (QoL) and IEFF-5 in group C. In addition, there were significant differences in Ss, QoL and IEFF-5 between Cernilton group and control group.

CONCLUSION:

In BPH patients with histological prostatitis after TURP, Cernilton can improve the lower urinary tract symptoms and sexual dysfunction depending on the grade of prostatitis.

KEYWORDS:

Prostatic hyperplasia; cernilton; histological prostatitis; transurethral resection of prostate

PMID:
26379934
PMCID:
PMC4565317

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center